I have been investing in pharma and bio for about 35 years. After yesterday's conference call, I just can't help thinking that this company has a few ( or more ) potentially explosive opportunities over the next few years. Not that any of them will be assuredly realized, with failures being a norm for the industry, but there is such lingering excitement.
I am talking about, for example, moving Adcetris towards earlier lines of treatment, SGN-33A for AML ( actually, there might be an even wider application in forms of myelodysplasia ), LIV-1 ADC in breast CA. Couple this with a solid royalty position and many milestones / partnerships, a good balance sheet and a reluctance of management to take on debt or issue an overwhelming number of new shares.........and the next three years "might" be quite amazing. Off course, we have to temper that with the reality that nothing usually ever goes smoothly or perfectly as planned with these sorts of ventures. Nonetheless, what I am simply saying is that the excitement ( at least for me ) is there.
Let's see what the next three years brings for anyone patient enough to hold this stock over this period of time.
Good luck to all!
CAUTION: Bias Disclosure: Ricardo owns a huge position in SGEN. Purchased mostly at relatively low prices years ago ( most lots at $4-8 ). He has sold off previously about 25% of his holdings to lock in a profit, but remains committed with the rest as a long term hold. Because of his large stake, his judgement may be quite distorted and he may be delusional so CAVEAT EMPTOR and do your own due diligence and research before investing.
Yes, they do seem to be excited about this at UCLA.
See also the videos at:
I have a long term position in nwbo. Still consider it quite risky and speculative, but the confidence in the results being reportedly witnessed by physicians at a leading medical center in encouraging.